Considering that we consistently observed a clear difference in cytotoxic activation by Fas agonists (E09, EP6, CH11, etc.)in tumor cells vs. Jurkat, it is conceivable to hypothesize differential influence of lipid rafts and associated proteins in tumor cells (vs. T or Jurkat cells) contributing toward more substantial autoinhibitory structural constraints to Fas activation in the membrane. The gene discussed is FAS; the disease is neoplasm.